The management of hypercholesterolemia in patients with coronary artery disease: Guidelines for primary care

Clinical Cornerstone

Volumn 1, Issue 1, 1998, Pages 51-64

  Vogel, Robert A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; PRIMARY HEALTH CARE;

CLINICAL PROTOCOLS; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; PRIMARY HEALTH CARE;

EID: 0032081421     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1098-3597(98)90006-0     Document Type: Article

References (24)

1. Anitschkov N. Experimental atherosclerosis in animals. In: Cowdry EV, ed. Arteriosclerosis: A Study of the Problem. New York, NY: Macmillan; 1933:271-322.
2. Gotto AM. Lipid lowering, regression and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, seventh council meeting. Circulation. 1995;92:646-656.
3. Gotto AM Jr. Results of recent large cholesterollowering trials and their implications for clinical management. Am J Cardiol. 1997;79:1663-1669.
4. LaRosa JC, Cleeman JI. Cholesterol lowering as a treatment for established coronary heart disease. Circulation. 1992;85:1229-1235.
5. Miller M, Vogel R. The Practice of Coronary Disease Prevention. Baltimore, Md: Williams & Wilkins; 1996:1-294.
6. Stamler J, Stamler R, Brown WV, et al. Serum cholesterol. Doing the right thing. Circulation. 1993;88: 1954-1960.
7. Vogel RA. Clinical implications of recent cholesterol lowering trials for the secondary prevention of coronary heart disease. Am J Managed Care. 1997;3:S83-S92.
8. Anderson M, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA. 1987;257:2176-2180.
9. Ericsson C-G, Nilsson J, Grip L, et al. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing. (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT].) Am J Cardiol. 1997;80:1125-1129.
10. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. NEJM. 1987;317:1237-1245.
11. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) results II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
12. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronaryartery bypass grafts. NEJM. 1997;336:153-162.
13. Sachs FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol. NEJM. 1996; 335:1001-1009.
14. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
15. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEJM. 1995;333:1301-1307.
16. The West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention study. Am J Cardiol. 1997;79:756-762.
17. Verschuren WM, Jacobs DR, Bloemberg BPM, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures, twenty-five year follow-up of the Seven Countries Study. JAMA. 1995; 274:131-136.
18. DeBusk RF, Miller NH, Superko HR, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 1994;120:721-729.
19. The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Summary of the second report. JAMA. 1993; 269:3015-3023.
20. Grundy SM, Balady GJ, Criqui MH, et al. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation. 1997;95:1683-1685.
21. Smith SC Jr, Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary artery disease. Circulation. 1995;92:2-4.
22. Cohen MV, Byrne M-J, Levine B, et al. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation. 1991;83:1294-1304.
23. Nieto FJ, Alonso J, Chambless LE, et al. Population awareness and control of hypertension and hypercholesterolemia. The Atherosclerosis Risk in Communities Study. Arch Intern Med. 1995;155:677-684.
24. Robert WC. Getting cardiologists interested in lipids. Am J Cardiol. 1993;72:744-745.